Subscribe to RSS
DOI: 10.1055/s-0036-1584350
Sphenoid Wing Dysplasia with Pulsatile Exophthalmos in Neurofibromatosis Type 1
Publication History
29 April 2016
10 May 2016
Publication Date:
09 June 2016 (online)
Neurofibromatosis type 1 (NF1) is a multisystem disease affecting the skin (café-au-lait spots, axillar/groin freckling), the central and peripheral nervous system (epilepsy, gliomas, neurofibromas), eyes (Lisch nodules), cardiovascular system (malformations), and the skeletal system.[1] Sphenoid wing dysplasia (SWD) occurs in 1 to 10% of NF1 patients.[2] SWD is often unilaterally and associated with plexiform neurofibromas in trigeminal nerve area. Absence or hypoplasia of sphenoid wing, that is, a wide opening of the superior orbital fissure can result in herniation of the temporal lobe, the dura or an arachnoid cyst causing an anterior shift of orbital content.[3] Our 2-year-old patient presented with a pulsating exophthalmos of the right eye due to temporal lobe herniation in a severe case of SWD ([Video 1], [Fig. 1A]). In addition to ptosis and the caudal dislocation and protrusion of the right eye a plexiform neurofibroma, which occurs frequently with SWD, was detected by magnetic resonance imaging ([Video 1], [Fig. 1B]).[4] The patient underwent reconstruction of the sphenoid wing because of increasing pulsatile exophthalmos. During postoperative follow-up, pulsatile exophthalmos was significantly reduced.
Quality:
-
References
- 1 Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol 2014; 13 (8) 834-843
- 2 Ferner RE, Huson SM, Thomas N , et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007; 44 (2) 81-88
- 3 Jacquemin C, Bosley TM, Svedberg H. Orbit deformities in craniofacial neurofibromatosis type 1. Am J Neuroradiol 2003; 24 (8) 1678-1682
- 4 Friedrich RE, Stelljes C, Hagel C, Giese M, Scheuer HA. Dysplasia of the orbit and adjacent bone associated with plexiform neurofibroma and ocular disease in 42 NF-1 patients. Anticancer Res 2010; 30 (5) 1751-1764